Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma

Glioblastoma (GBM) is among the most aggressive of brain tumors and confers a dismal prognosis despite advances in surgical technique, radiation delivery methods, chemotherapy, and tumor-treating fields. While immunotherapy (IT) has improved the care of several adult cancers with previously dismal p...

Full description

Bibliographic Details
Main Authors: Mara De Martino, Oscar Padilla, Camille Daviaud, Cheng-Chia Wu, Robyn D. Gartrell, Claire Vanpouille-Box
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.671044/full
id doaj-25d1ae30496342289d91bb44be7019f2
record_format Article
spelling doaj-25d1ae30496342289d91bb44be7019f22021-05-20T06:55:11ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-05-011110.3389/fonc.2021.671044671044Exploiting Radiation Therapy to Restore Immune Reactivity of GlioblastomaMara De Martino0Oscar Padilla1Camille Daviaud2Cheng-Chia Wu3Cheng-Chia Wu4Robyn D. Gartrell5Claire Vanpouille-Box6Claire Vanpouille-Box7Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, United StatesDepartment of Radiation Oncology, Columbia University Irving Medical Center, New York, NY, United StatesDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, United StatesDepartment of Radiation Oncology, Columbia University Irving Medical Center, New York, NY, United StatesHerbert Irving Comprehensive Cancer Center, New York, NY, United StatesDepartment of Pediatrics, Pediatric Hematology/Oncology/SCT, Columbia University Irving Medical Center, New York, NY, United StatesDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, United StatesSandra and Edward Meyer Cancer Center, New York, NY, United StatesGlioblastoma (GBM) is among the most aggressive of brain tumors and confers a dismal prognosis despite advances in surgical technique, radiation delivery methods, chemotherapy, and tumor-treating fields. While immunotherapy (IT) has improved the care of several adult cancers with previously dismal prognoses, monotherapy with IT in GBM has shown minimal response in first recurrence. Recent discoveries in lymphatics and evaluation of blood brain barrier offer insight to improve the use of ITs and determine the best combinations of therapies, including radiation. We highlight important features of the tumor immune microenvironment in GBM and potential for combining radiation and immunotherapy to improve prognosis in this devastating disease.https://www.frontiersin.org/articles/10.3389/fonc.2021.671044/fullglioblastomaradiotherapyimmunotherapyantigenicityadjuvanticityimmunosuppression
collection DOAJ
language English
format Article
sources DOAJ
author Mara De Martino
Oscar Padilla
Camille Daviaud
Cheng-Chia Wu
Cheng-Chia Wu
Robyn D. Gartrell
Claire Vanpouille-Box
Claire Vanpouille-Box
spellingShingle Mara De Martino
Oscar Padilla
Camille Daviaud
Cheng-Chia Wu
Cheng-Chia Wu
Robyn D. Gartrell
Claire Vanpouille-Box
Claire Vanpouille-Box
Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma
Frontiers in Oncology
glioblastoma
radiotherapy
immunotherapy
antigenicity
adjuvanticity
immunosuppression
author_facet Mara De Martino
Oscar Padilla
Camille Daviaud
Cheng-Chia Wu
Cheng-Chia Wu
Robyn D. Gartrell
Claire Vanpouille-Box
Claire Vanpouille-Box
author_sort Mara De Martino
title Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma
title_short Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma
title_full Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma
title_fullStr Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma
title_full_unstemmed Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma
title_sort exploiting radiation therapy to restore immune reactivity of glioblastoma
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2021-05-01
description Glioblastoma (GBM) is among the most aggressive of brain tumors and confers a dismal prognosis despite advances in surgical technique, radiation delivery methods, chemotherapy, and tumor-treating fields. While immunotherapy (IT) has improved the care of several adult cancers with previously dismal prognoses, monotherapy with IT in GBM has shown minimal response in first recurrence. Recent discoveries in lymphatics and evaluation of blood brain barrier offer insight to improve the use of ITs and determine the best combinations of therapies, including radiation. We highlight important features of the tumor immune microenvironment in GBM and potential for combining radiation and immunotherapy to improve prognosis in this devastating disease.
topic glioblastoma
radiotherapy
immunotherapy
antigenicity
adjuvanticity
immunosuppression
url https://www.frontiersin.org/articles/10.3389/fonc.2021.671044/full
work_keys_str_mv AT marademartino exploitingradiationtherapytorestoreimmunereactivityofglioblastoma
AT oscarpadilla exploitingradiationtherapytorestoreimmunereactivityofglioblastoma
AT camilledaviaud exploitingradiationtherapytorestoreimmunereactivityofglioblastoma
AT chengchiawu exploitingradiationtherapytorestoreimmunereactivityofglioblastoma
AT chengchiawu exploitingradiationtherapytorestoreimmunereactivityofglioblastoma
AT robyndgartrell exploitingradiationtherapytorestoreimmunereactivityofglioblastoma
AT clairevanpouillebox exploitingradiationtherapytorestoreimmunereactivityofglioblastoma
AT clairevanpouillebox exploitingradiationtherapytorestoreimmunereactivityofglioblastoma
_version_ 1721435643657060352